Company Filing History:
Years Active: 2023
Title: The Innovations of Harvey Che in Bicyclic Peptide Ligands
Introduction
Harvey Che, an innovative inventor based in Cambridge, GB, has made a significant contribution to the field of biochemistry through his inventive work on bicyclic peptide ligands. His research focuses on the molecular interactions that can be harnessed for therapeutic purposes, particularly in relation to the immune system.
Latest Patents
One of Harvey Che's notable patents is titled "Bicyclic Peptide Ligands Specific for OX40." This invention involves polypeptides that are covalently attached to molecular scaffolds, allowing for the formation of multiple peptide loops between the scaffold's attachment points. The invention specifically outlines how these peptides can bind to the OX40 receptor, an important target in immunology. Additionally, the patent encompasses multimeric binding complexes that act as functional agonists of OX40 and includes drug conjugates linked to effector groups for the prevention, suppression, or treatment of diseases associated with OX40.
Career Highlights
Harvey Che is associated with Bicycletx Limited, a company focused on advancing healthcare through innovative molecular designs. With his expertise in peptide chemistry, he has contributed to the development of therapeutic solutions that hold potential for significant impact in medicine.
Collaborations
Throughout his career, Harvey has collaborated with talented individuals, including Tom Li Stephen and Kevin McDonnell. These collaborations foster creativity and innovation in the research and development of new therapeutic agents, enhancing the overall progress in their projects.
Conclusion
Through his inventive work and collaborations, Harvey Che has established himself as a promising inventor in the field of peptide ligands. His patent on bicyclic peptide ligands specific for OX40 demonstrates the potential applications of his research in addressing various medical conditions, showcasing the impact of innovative thinking in the biotechnology sector.